CTMX NASDAQ
CytomX Therapeutics, Inc.
1W: -4.7%
1M: -17.4%
3M: -30.8%
YTD: -47.5%
1Y: -32.4%
3Y: +66.4%
5Y: -55.4%
$2.31
+0.09 (+3.82%)
After Hours: $2.38 (+0.07, +3.03%)
Weekly Expected Move ±9.0%
$2
$2
$2
$3
$3
Credit Risk of going bust: lower than 54% of companies Debt: 1.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down 99.7%), CytomX Therapeutics, Inc. would be worth roughly what it owes.
Total debt $5.7M against a stock market value of $484.8M.
Distance to default 5.54 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $3.6M (short-term plus half of long-term), stock volatility 83.8%; Altman Z'' 1.92. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down 99.7%), CytomX Therapeutics, Inc. would be worth roughly what it owes.
Total debt $5.7M against a stock market value of $484.8M.
Distance to default 5.54 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $3.6M (short-term plus half of long-term), stock volatility 83.8%; Altman Z'' 1.92. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships5
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2023-01-05
Earliest Filing
2023-08-24
Latest Filing
partner: 5
Counterparties (Filed by CTMX)
5 relationshipsCompanies named in CTMX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| AbbVie Global Enterprises Ltd. | ABBV | partner | Entered into a Transition Agreement granting CytomX exclusive worldwide rights to develop CX-2029. | 2023-08-24 | View |
| AbbVie Ireland Unlimited Company | ABBV | partner | Affiliate entity of AbbVie; original collaborator whose terminated agreement was superseded by the new Transition Agreem | 2023-08-24 | View |
| Seattle Genetics, Inc. | — | partner | Licensed linker payload technology to CytomX; eligible to receive future milestones and royalties. | 2023-08-24 | View |
| ModernaTX, Inc. | MRNA | partner | Entered into a collaboration and license agreement for mRNA-based investigational therapies. | 2023-01-05 | View |
| Moderna, Inc. | MRNA | partner | Parent company of ModernaTX, Inc., entered into a collaboration and license agreement for mRNA-based investigational the | 2023-01-05 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-07-27 | Officer/Director Change | View | |
| 2026-06-22 | Officer/Director Change; Bylaws Amendment; Shareholder Vote; Exhibits | View | |
| 2026-06-03 | Material Agreement | Agreement | View |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-03-19 | Other Events; Exhibits | View | |
| 2026-03-16 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-13 | Other Events | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-13 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-28 | Other Events | View | |
| 2025-05-13 | Other Events; Financial Statements and Exhibits | View | |
| 2025-05-12 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-03-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-26 | Notice of Delisting or Transfer | View | |
| 2025-02-03 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-01-06 | Costs Associated with Exit or Disposal Activities | View | |
| 2024-11-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-08-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR